Isopentaquine

Isopentaquine is an orally active antimalarial agent. Isopentaquine induces mild morphological changes in the exoerythrocytic stage of Plasmodium fallax, with a ED₅₀ of 6.7 mg/L. Isopentaquine causes degenerative changes in the development of Plasmodium oocysts in infected mosquitoes. Isopentaquine reduces the infectivity of Plasmodium falciparum gametocytes. Isopentaquine impairs sympathetic cardiovascular reflexes. Isopentaquine decreases the recurrence rate and total disease duration of Plasmodium vivax infection. Isopentaquine can be used in malaria-related research^[1][2][3]. In Vitro:Isopentaquine (10-20 mg/L; 48 h) induces mild morphological changes in exoerythrocytic stages of Plasmodium fallax grown in embryonic turkey brain cells, with an ED₅₀ of 6.7 mg/l, making it less effective than other tested 8-aminoquinolines^[1].
Isopentaquine reduces the infectivity of Plasmodium falciparum gametocytes^[2]. In Vivo:Isopentaquine (0.02% concentration; oral; via feeding) causes degenerative changes in Plasmodium falciparum oocyst development in infected mosquitoes^[2].
Isopentaquine (Large doses; prolonged period) impairs sympathetic cardiovascular reflexes in dogs and monkeys via medullary cell group destruction^[2].